

Alexander Z Wei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9926816/publications.pdf>

Version: 2024-02-01

8
papers

82
citations

1684188

5
h-index

1872680

6
g-index

9
all docs

9
docs citations

9
times ranked

132
citing authors

#	ARTICLE	IF	CITATIONS
1	Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 997-1004.	3.1	7
2	New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma. <i>Cancer Gene Therapy</i> , 2022, 29, 1819-1826.	4.6	10
3	Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far. <i>Seminars in Oncology</i> , 2021, 48, 57-68.	2.2	5
4	Biological and Clinical Factors Contributing to the Metabolic Heterogeneity of Hospitalized Patients with and without COVID-19. <i>Cells</i> , 2021, 10, 2293.	4.1	37
5	The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients. <i>Frontiers in Medicine</i> , 2021, 8, 817305.	2.6	7
6	Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 13.	6.2	5
7	Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study. <i>Blood</i> , 2019, 134, 3196-3196.	1.4	0
8	A phase 1/2 study of carfilzomib, bendamustine, and dexamethasone (CBD) in newly diagnosed multiple myeloma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8029-8029.	1.6	0